Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.230
+0.150 (4.87%)
At close: Sep 4, 2026, 4:00 PM EDT
3.200
-0.030 (-0.93%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Editas Medicine Revenue
Editas Medicine had revenue of $11.89M in the quarter ending June 30, 2026, with 232.31% growth. This brings the company's revenue in the last twelve months to $47.01M, up 20.83% year-over-year. In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth.
Revenue (ttm)
$47.01M
Revenue Growth
+20.83%
P/S Ratio
10.55
Revenue / Employee
$540,287
Employees
87
Market Cap
496.06M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Ginkgo Bioworks Holdings | 132.42M |
| Prothena Corporation | 54.53M |
| C4 Therapeutics | 35.04M |
| Ocugen | 4.58M |
| Inhibikase Therapeutics | 1.00 |
EDIT News
- 4 days ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - Editas Medicine files $400M mixed securities shelf - TheFly
- 5 days ago - Editas Medicine Registration statement: Registration filing - Filings
- 18 days ago - Editas Medicine initiated with a Buy at Ladenburg - TheFly
- 4 weeks ago - Editas Medicine reports Q2 EPS (15c), consensus (28c) - TheFly
- 4 weeks ago - Editas Medicine Announces Second Quarter 2026 Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Editas Medicine Earnings release: Q2 2026 - Filings
- 4 weeks ago - Editas Medicine Quarterly report: Q2 2026 - Filings